AI-generated summary
The authors report a randomized controlled trial in 90 stroke patients with post-stroke cognitive impairment, comparing a red-light device at 630 nm with sham stimulation over 3 months. Patients receiving red light showed improved cognition, reduced anxiety and depression, and better daily living scores at 6 months, along with changes in formaldehyde-related markers. The authors describe the findings as exploratory.
- Participants
- 90
- Who or what was studied
- Patients with post-stroke cognitive impairment (PSCI) following acute stroke
- Wavelengths
- 630 nm
- Limits stated in the abstract
- The authors describe the study as exploratory, and the abstract reports 38 and 44 completers in the two groups, implying attrition from the 90 enrolled.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Introduction
Acute stroke patients often develop post-stroke cognitive impairment (PSCI) and dysthymic disorders. Formaldehyde (FA) induces cognitive decline and depression; while red light (RL) at 630 nm can degrade FA by activating FA-dehydrogenase (FDH). This study investigates the therapeutic effects of a novel RL device on cognitive function and neuropsychiatric symptoms in patients with PSCI.
Methods
This was an exploratory, parallel-group, randomized controlled trial with concealed allocation, assessor blinding and intention-to-treat analysis. Stroke patients (n = 90) were enrolled. A total of 38 patients in the PSCI group and 44 patients in the PSCI-RL group completed the study. Participants were followed for 6 months, during which the intervention phase comprised 3 months of RL therapy or sham stimulation, followed by continued follow-up. Cognitive [Montreal Cognitive Assessment (MoCA)/Mini-Mental State Examination (MMSE)], neuropsychiatric [Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA)], and functional [Barthel Index (BI)] assessments were conducted at baseline and 6 months. Blood and urine levels of key enzymes and metabolites involved in FA metabolism were quantified, including semicarbazide-sensitive amine oxidase (SSAO, an FA-generating enzyme), FDH (an FA-degrading enzyme), cytochrome c (Cyt-c), FA, hydrogen peroxide (H2O2, a marker of FA generation), and coenzyme Q10 (CoQ10, an endogenous FA scavenger).
Results
The phototherapy device improved cognitive abilities, reduced anxiety and depression, lessened stroke severity, and enhanced daily living activities in the PSCI-RL group at 6 months. Additionally, RL therapy altered FA metabolism, as it lowered SSAO and H2O2 levels and increased FDH, Cyt-c, and CoQ10 in blood and/or urine of PSCI patients.
Conclusions
RL therapy may improve clinical symptoms in post-stroke patients by modulating FA metabolism, suggesting a safe and promising approach for treatment and rehabilitation. CLINICAL
Trial Registration
https://www.chictr.org.cn/showproj.html?proj=159956, Identifier: ChiCTR2200058991.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Stroke, Photobiomodulation, Depression, Montreal Cognitive Assessment, Anxiety, Intention-to-treat analysis, Randomized controlled trial, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.